1ILMN Stock Overview

Provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. More details

1ILMN fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	4/6
Past Performance	0/6
Financial Health	5/6
Dividends	1/6

Rewards

Earnings are forecast to grow 52.35% per year

Risk Analysis

Volatile share price over the past 3 months compared to the Italian market

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Illumina, Inc. Competitors

Fine Foods & Pharmaceuticals N.T.M

BIT:FF

€169.9m

Recordati Industria Chimica e Farmaceutica

BIT:REC

€10.9b

Sartorius

XTRA:SRT3

€14.4b

West Pharmaceutical Services

NYSE:WST

US$16.5b

Price History & Performance

Summary of share price highs, lows and changes for Illumina
Historical stock prices
Current Share Price	US$79.20
52 Week High	US$138.00
52 Week Low	US$77.70
Beta	1.17
1 Month Change	-13.94%
3 Month Change	-38.49%
1 Year Change	-37.30%
3 Year Change	-74.20%
5 Year Change	-67.10%
Change since IPO	-72.37%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	1ILMN	IT Life Sciences	IT Market
7D	2.7%	1.2%	0.9%
1Y	-37.3%	-18.6%	12.2%

Return vs Industry: 1ILMN underperformed the Italian Life Sciences industry which returned -18.6% over the past year.

Return vs Market: 1ILMN underperformed the Italian Market which returned 12.2% over the past year.

Price Volatility

Is 1ILMN's price volatile compared to industry and market?
1ILMN volatility
1ILMN Average Weekly Movement	7.1%
Life Sciences Industry Average Movement	6.7%
Market Average Movement	4.6%
10% most volatile stocks in IT Market	8.2%
10% least volatile stocks in IT Market	2.7%

Stable Share Price: 1ILMN's share price has been volatile over the past 3 months compared to the Italian market.

Volatility Over Time: 1ILMN's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of Italian stocks.

About the Company

Founded	Employees	CEO	Website
1998	9,000	Jacob Thaysen	www.illumina.com

Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services.

Illumina, Inc. Fundamentals Summary

How do Illumina's earnings and revenue compare to its market cap?
1ILMN fundamental statistics
Market cap	€12.83b
Earnings (TTM)	-€1.13b
Revenue (TTM)	€4.04b

3.2x

P/S Ratio

-11.4x

P/E Ratio

Is 1ILMN overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
1ILMN income statement (TTM)
Revenue	US$4.37b
Cost of Revenue	US$1.38b
Gross Profit	US$2.99b
Other Expenses	US$4.21b
Earnings	-US$1.22b

Last Reported Earnings

Dec 29, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-7.72
Gross Margin	68.37%
Net Profit Margin	-27.97%
Debt/Equity Ratio	83.8%

How did 1ILMN perform over the long term?

See historical performance and comparison

Dividends

3.7%

Current Dividend Yield

n/a

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/03/23 10:11
End of Day Share Price	2025/03/21 00:00
Earnings	2024/12/29
Annual Earnings	2024/12/29

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Illumina, Inc. is covered by 54 analysts. 23 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Jasper Hellweg	Argus Research Company
James Francis Mainwaring	Atlantic Equities LLP
Catherine Ramsey Schulte	Baird